EUVIMEDEUVIMED entdecken
Open Access

Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database

Kaori Ito, Takenao Koseki, Misaki Morisaku, Shigeki Yamada, Nobuki Hayakawa

In Vivo · 2024

DOI: 10.21873/invivo.13520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Kaori Ito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Meijo University, Nagoya, Japan; itoka@meijo-u.ac.jp. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Cytomegalovirus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Patients with malignant lymphoma, in a latent state of weakened immune function, are at risk of chemotherapy-induced immunosuppression and cytomegalovirus (CMV) infection. Concomitant therapy with bendamustine and rituximab or obinutuzumab intensifies immunosuppression, potentially affecting CMV onset. This study aimed to assess CMV onset differences between bendamustine monotherapy and combination therapy with rituximab or obinutuzumab using the Japanese Adverse Drug Event Report database (JADER). PATIENTS AND METHODS: A JADER analysis dataset (April 2004 to September 2022) defined CMV infection using 31 preferred term (PT) words from MedDRA 25.1J HLT "Cytomegalovirus infection (10011827)". Reporting odds ratios (ROR) calculated CMV infection signals for bendamustine monotherapy, rituximab, obinutuzumab, bendamustine+rituximab (BR), and bendamustine+obinutuzumab (GB). ROR confidence intervals exceeding 1 indicated a CMV signal. Days of CMV infection were calculated based on adverse event onset and administration start. RESULTS: CMV signals were confirmed for monotherapy and combination therapies. CMV infection durations (median, interquartile range) were 41.0 days (23.5-69.5) for bendamustine monotherapy, 63.5 days (35.2-95.0) for BR, and 61.0 days (33.0-102.5) for GB, with cases exceeding 200 days. CONCLUSION: JADER analysis detected significant CMV signals for rituximab, obinutuzumab, and bendamustine. Caution may be warranted 7-9 months post-bendamustine administration, necessitating further investigation, including cell-mediated immunity suppression assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsCytomegalovirus InfectionsHumansBendamustine HydrochlorideRituximabCytomegalovirusPharmaceutical PreparationsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

BendamustineJapanese Adverse Drug Event Report databaseanti-CD20 monoclonal antibodiescytomegalovirus infection

Substanzen

Bendamustine HydrochlorideRituximabPharmaceutical Preparations

Autor:innen und Institutionen

  • Faculty of Pharmacy, Meijo University, Nagoya, Japan; itoka@meijo-u.ac.jp.
  • Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
  • Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
  • Faculty of Pharmacy, Meijo University, Nagoya, Japan.

Zitieren

APA

Ito, K., Koseki, T., Morisaku, M., Yamada, S., & Hayakawa, N. (2024). Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database. In Vivo. https://doi.org/10.21873/invivo.13520

Vancouver

Ito K, Koseki T, Morisaku M, Yamada S, Hayakawa N. Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database. In Vivo. 2024. doi:10.21873/invivo.13520

BibTeX
@article{Ito2024,
  author = {Ito, Kaori and Koseki, Takenao and Morisaku, Misaki and Yamada, Shigeki and Hayakawa, Nobuki},
  title = {Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database},
  journal = {In Vivo},
  year = {2024},
  doi = {10.21873/invivo.13520}
}
Kostenlos starten →